المؤلفون: Köbel, Martin, Kang, Eun-Young, Weir, Ashley, Rambau, Peter F, Lee, Cheng-Han, Nelson, Gregg S, Ghatage, Prafull, Meagher, Nicola S, Riggan, Marjorie J, Alsop, Jennifer, Anglesio, Michael S, Beckmann, Matthias W, Bisinotto, Christiani, Boisen, Michelle, Boros, Jessica, Brand, Alison H, Brooks-Wilson, Angela, Carney, Michael E, Coulson, Penny, Courtney-Brooks, Madeleine, Cushing-Haugen, Kara L, Cybulski, Cezary, Deen, Suha, El-Bahrawy, Mona A, Elishaev, Esther, Erber, Ramona, Fereday, Sian, AOCS Group, Fischer, Anna, Gayther, Simon A, Barquin-Garcia, Arantzazu, Gentry-Maharaj, Aleksandra, Gilks, C Blake, Gronwald, Helena, Grube, Marcel, Harnett, Paul R, Harris, Holly R, Hartkopf, Andreas D, Hartmann, Arndt, Hein, Alexander, Hendley, Joy, Hernandez, Brenda Y, Huang, Yajue, Jakubowska, Anna, Jimenez-Linan, Mercedes, Jones, Michael E, Kennedy, Catherine J, Kluz, Tomasz, Koziak, Jennifer M, Lesnock, Jaime, Lester, Jenny, Lubiński, Jan, Longacre, Teri A, Lycke, Maria, Mateoiu, Constantina, McCauley, Bryan M, McGuire, Valerie, Ney, Britta, Olawaiye, Alexander, Orsulic, Sandra, Osorio, Ana, Paz-Ares, Luis, Ramón Y Cajal, Teresa, Rothstein, Joseph H, Ruebner, Matthias, Schoemaker, Minouk J, Shah, Mitul, Sharma, Raghwa, Sherman, Mark E, Shvetsov, Yurii B, Singh, Naveena, Steed, Helen, Storr, Sarah J, Talhouk, Aline, Traficante, Nadia, Wang, Chen, Whittemore, Alice S, Widschwendter, Martin, Wilkens, Lynne R, Winham, Stacey J, Benitez, Javier, Berchuck, Andrew, Bowtell, David D, Candido Dos Reis, Francisco J, Campbell, Ian, Cook, Linda S, DeFazio, Anna, Doherty, Jennifer A, Fasching, Peter A, Fortner, Renée T, García, María J, Goodman, Marc T, Goode, Ellen L, Gronwald, Jacek, Huntsman, David G, Karlan, Beth Y, Kelemen, Linda E, Kommoss, Stefan, Le, Nhu D, Martin, Stewart G, Menon, Usha, Modugno, Francesmary, Pharoah, Paul Dp, Schildkraut, Joellen M, Sieh, Weiva, Staebler, Annette, Sundfeldt, Karin, Swerdlow, Anthony J, Ramus, Susan J, Brenton, James D

المصدر: essn: 2056-4538 ; nlmid: 101658534

مصطلحات موضوعية: TP53, clear cell, endometrioid, high-grade serous carcinoma, ovarian cancer, p53, prognosis, Humans, Female, Tumor Suppressor Protein p53, Ovarian Neoplasms, Carcinoma, Ovarian Epithelial

الوصف: Funder: Biomedical Research Centre ; Funder: European Regional Development Fund ; Funder: Mayo Foundation for Medical Education and Research ; Funder: Pomeranian Medical University ; Funder: Pomorski Uniwersytet Medyczny W Szczecinie ; Funder: Cancer Council NSW ; Funder: Cancer Institute NSW ; Funder: Deutsches Krebsforschungszentrum ; Funder: The BC Cancer Foundation ; Funder: University College London Hospitals Biomedical Research Centre ; Funder: Breast Cancer Now ; Funder: Cancer Council Tasmania ; Funder: Clinical Academic Reserve ; Funder: ELAN Funds of the University of Erlangen-Nuremberg ; Funder: Fondo Europeo de Desarrollo Regional ; Funder: National Institute for Health Research (NIHR) ; Funder: National Institute for Health and Care Research ; Funder: Ovarian Cancer Australia ; Funder: Queensland Cancer Fund ; Funder: Cancer Council New South Wales ; Funder: Fred C. and Katherine B. Andersen Foundation ; Funder: German Cancer Research Center ; Funder: Institute of Cancer Research ; Funder: Mayo Foundation ; Funder: Minnesota Ovarian Cancer Alliance ; Funder: Peter MacCallum Foundation ; Funder: University of Cambridge ; Funder: Cancer Foundation of Western Australia ; Funder: VGH and UBC Hospital Foundation ; Funder: Cancer Council Victoria ; Funder: NHS ; Funder: UK National Institute for Health Research ; Funder: Cancer Council South Australia ; Funder: Oak Foundation ; Funder: Sydney West Translational Cancer Research Centre ; Our objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high-grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carcinoma [CCC]) using a large multi-institutional cohort from the Ovarian Tumor Tissue Analysis (OTTA) consortium. p53 expression was assessed on 6,678 cases represented on tissue microarrays from 25 participating OTTA study sites using a previously validated immunohistochemical (IHC) assay as a surrogate for the presence and functional ...

وصف الملف: application/pdf

العلاقة: https://www.repository.cam.ac.uk/handle/1810/348813Test

الإتاحة: https://doi.org/10.17863/CAM.96239Test
https://www.repository.cam.ac.uk/handle/1810/348813Test

المؤلفون: Barquín García, Arantzazu, Palacios-Zambrano, Sara, Lozano Alarcón, Felipe, Paumard-Hernández, Beatriz, Quiralte Pulido, Miguel, Navarro, Paloma, Rodríguez, Laura, Salas Villar, Isabel, García-Donas, Jesús

المصدر: Journal of the National Comprehensive Cancer Network ; volume 22, issue 1D, page 1-5 ; ISSN 1540-1405 1540-1413

مصطلحات موضوعية: Oncology

الوصف: This report presents the case of a 62-year-old woman who was diagnosed in 1999 with stage I cervical carcinoma treated by surgical resection. In 2021, she presented to the emergency department with a complaint of predominantly right-sided lower back pain. A CT scan of the lumbosacral region revealed a bone lesion in the L5 vertebra and retroperitoneal lymphadenopathies suggestive of malignancy. Histology of the L5 vertebra biopsy showed a poorly differentiated carcinoma with an inconclusive immunophenotypic profile. Treatment for carcinoma of unknown primary was started with a combination of carboplatin and paclitaxel every 21 days. A genomic study of the biopsy specimen performed on the FoundationOne CDx platform identified a nonhuman genetic signature compatible with HPV. The presence of HPV 18 DNA in the specimen was confirmed by PCR-reverse dot blot, and the immunophenotypic profile was expanded, revealing strong and diffuse p16 expression, thus corroborating the molecular findings. In view of these findings, the case was reclassified as a recurrence of the cervical adenocarcinoma that had been diagnosed and treated 23 years earlier. Based on the new results, and according to first-line cervical carcinoma protocols, bevacizumab at 15 mg/kg every 21 days was added to her chemotherapy regimen. The identification of HPV DNA sequences by next-generation sequencing facilitated the correct diagnosis and led to a modification of the first-line therapeutic approach.

الإتاحة: https://doi.org/10.6004/jnccn.2023.7079Test
https://jnccn.org/view/journals/jnccn/22/1D/article-p1_5.xmlTest
https://jnccn.org/downloadpdf/journals/jnccn/22/1D/article-p1_5.xmlTest

المؤلفون: Sevillano Fernández, Elena, Madurga Lacalle, Rodrigo, Rodriguez Moreno, Juan Francisco, Barquín García, Arantzazu, Yagüe Fernández, Mónica, Navarro Alcaraz, Paloma, Barba Llacer, María, Quiralte Pulido, Miguel, García-Donás Jiménez, Jesús

مصطلحات موضوعية: Metastatic urothelial cancer

الوصف: Fibroblast growth factor receptor (FGFR) genomic alterations (GAs) represent an actionable target, key to the pathogenesis of some urothelial cancers (UCs). Though FGFR GAs are common in noninvasive UC, little is known about their role in the metastatic(m) setting and response to therapy. This study aimed to assess the impact of FGFR alterations on sensitivity to systemic treatments and survival and to validate Bajorin’s and Bellmunt’s prognostic scores in mUC patients according to their FGFR status. We retrospectively analyzed data from 98 patients with tumor-sequenced UC who received treatment between January 2010 and December 2020. Up to 77 developed metastatic disease and were deemed the study population. Twenty-six showed FGFR GAs. A trend toward a better response to cisplatin and checkpoint inhibitors was suggested favoring FGFR GA tumors. FGFR GA patients who received an FGFR inhibitor as first-line had poorer responses compared with other options (20% vs. 68.4%, p = 0.0065). Median PFS was 6 vs. 5 months in the FGFR GA vs. FGFR WT cohort (p = 0.71). Median OS was significantly worse in the FGFR GA vs. FGFR WT cohort (16.2 vs. 31.9 months, p = 0.045). Multivariate analyses deemed FGFR GAs as a factor independently associated with the outcome (HR 2.59 (95% CI 1.21–5.55)). Bajorin’s model correctly predicted clinical outcomes in the whole study population but not in FGFR GA cases. FGFR GAs are a relevant biomarker in mUC that could condition the response to systemic therapy. New prognostic models, including this molecular determination, should be designed and validated. ; post-print ; 2300 KB

العلاقة: https://www.mdpi.com/2077-0383/11/15/4483Test; https://hdl.handle.net/10641/3344Test

الإتاحة: https://doi.org/10.3390/jcm11154483Test
https://hdl.handle.net/10641/3344Test

المؤلفون: Kang, Eun Young, Millstein, Joshua, Popovic, Gordana, Meagher, Nicola S., Bolithon, Adelyn, Talhouk, Aline, Chiu, Derek S., Anglesio, Michael S., Leung, Betty, Tang, Katrina, Lambie, Neil, Pavanello, Marina, Da-anoy, Annalyn, Lambrechts, Diether, Loverix, Liselore, Olbrecht, Siel, Bisinotto, Christiani, Garcia-Donas, Jesus, Ruiz-Llorente, Sergio, Yagüe-Fernandez, Monica, Edwards, Robert P., Elishaev, Esther, Olawaiye, Alexander, Taylor, Sarah, Ataseven, Beyhan, du Bois, Andreas, Harter, Philipp, Lester, Jenny, Høgdall, Claus K., Armasu, Sebastian M., Huang, Yajue, Vierkant, Robert A., Wang, Chen, Winham, Stacey J., Heublein, Sabine, Kommoss, Felix K.F., Cramer, Daniel W., Sasamoto, Naoko, van-Wagensveld, Lilian, Lycke, Maria, Mateoiu, Constantina, Joseph, Janine, Pike, Malcolm C., Odunsi, Kunle, Tseng, Chiu Chen, Pearce, Celeste L., Bilic, Sanela, Conrads, Thomas P., Hartmann, Arndt, Hein, Alexander, Jones, Michael E., Leung, Yee, Beckmann, Matthias W., Ruebner, Matthias, Schoemaker, Minouk J., Terry, Kathryn L., El-Bahrawy, Mona A., Coulson, Penny, Etter, John L., LaVigne-Mager, Katherine, Andress, Juergen, Grube, Marcel, Fischer, Anna, Neudeck, Nina, Robertson, Greg, Farrell, Rhonda, Barlow, Ellen, Quinn, Carmel, Hettiaratchi, Anusha, Casablanca, Yovanni, Erber, Ramona, Stewart, Colin J.R., Tan, Adeline, Yu, Yu, Boros, Jessica, Brand, Alison H., Harnett, Paul R., Kennedy, Catherine J., Nevins, Nikilyn, Morgan, Terry, Fasching, Peter A., Vergote, Ignace, Swerdlow, Anthony J., Candido dos Reis, Francisco J., Maxwell, G. Larry, Neuhausen, Susan L., Barquin-Garcia, Arantzazu, Modugno, Francesmary, Moysich, Kirsten B., Crowe, Philip J., Hirasawa, Akira, Heitz, Florian, Karlan, Beth Y., Goode, Ellen L., Sinn, Peter, Horlings, Hugo M., Høgdall, Estrid, Sundfeldt, Karin, Kommoss, Stefan, Staebler, Annette, Wu, Anna H., Cohen, Paul A., DeFazio, Anna, Lee, Cheng Han, Steed, Helen, Le, Nhu D., Gayther, Simon A., Lawrenson, Kate, Pharoah, Paul D.P., Konecny, Gottfried, Cook, Linda S., Ramus, Susan J., Kelemen, Linda E., Köbel, Martin

المصدر: Kang , E Y , Millstein , J , Popovic , G , Meagher , N S , Bolithon , A , Talhouk , A , Chiu , D S , Anglesio , M S , Leung , B , Tang , K , Lambie , N , Pavanello , M , Da-anoy , A , Lambrechts , D , Loverix , L , Olbrecht , S , Bisinotto , C , Garcia-Donas , J , Ruiz-Llorente , S , Yagüe-Fernandez , M , Edwards , R P , Elishaev , E , Olawaiye , A , Taylor , ....

مصطلحات موضوعية: High-grade serous carcinoma, MCM3, Proliferation

الوصف: Tubo-ovarian high-grade serous carcinomas (HGSC) are highly proliferative neoplasms that generally respond well to platinum/taxane chemotherapy. We recently identified minichromosome maintenance complex component 3 (MCM3), which is involved in the initiation of DNA replication and proliferation, as a favorable prognostic marker in HGSC. Our objective was to further validate whether MCM3 mRNA expression and possibly MCM3 protein levels are associated with survival in patients with HGSC. MCM3 mRNA expression was measured using NanoString expression profiling on formalin-fixed and paraffin-embedded tissue (N = 2355 HGSC) and MCM3 protein expression was assessed by immunohistochemistry (N = 522 HGSC) and compared with Ki-67. Kaplan–Meier curves and the Cox proportional hazards model were used to estimate associations with survival. Among chemotherapy-naïve HGSC, higher MCM3 mRNA expression (one standard deviation increase in the score) was associated with longer overall survival (HR = 0.87, 95% CI 0.81–0.92, p < 0.0001, N = 1840) in multivariable analysis. MCM3 mRNA expression was highest in the HGSC C5.PRO molecular subtype, although no interaction was observed between MCM3, survival and molecular subtypes. MCM3 and Ki-67 protein levels were significantly lower after exposure to neoadjuvant chemotherapy compared to chemotherapy-naïve tumors: 37.0% versus 46.4% and 22.9% versus 34.2%, respectively. Among chemotherapy-naïve HGSC, high MCM3 protein levels were also associated with significantly longer disease-specific survival (HR = 0.52, 95% CI 0.36–0.74, p = 0.0003, N = 392) compared to cases with low MCM3 protein levels in multivariable analysis. MCM3 immunohistochemistry is a promising surrogate marker of proliferation in HGSC.

وصف الملف: application/pdf

الإتاحة: https://doi.org/10.1007/s00428-021-03232-0Test
https://curis.ku.dk/portal/da/publications/mcm3-is-a-novel-proliferation-marker-associated-with-longer-survival-for-patients-with-tuboovarian-highgrade-serous-carcinomaTest(fa84f260-a314-4bbb-b73c-623a5e36a7aa).html
https://curis.ku.dk/ws/files/358652757/nihms_1765278.pdfTest

المؤلفون: Serrano Domingo, Juan José, Alonso Gordoa, Teresa, Lorca Álvaro, Javier, Molina-Cerrillo, Javier, Barquín García, Arantzazu, Martínez Sáez, Olga, Burgos Revilla, Javier, Carrato, Alfredo, Álvarez Rodríguez, Sara

المصدر: Therapeutic Advances in Urology ; volume 13, page 175628722110433 ; ISSN 1756-2872 1756-2880

الوصف: Introduction: Androgenic deprivation therapies have been linked to the development of metabolic syndrome (MS) and cardiovascular diseases, which may lead to a poorer survival in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC). We aimed to analyze whether some cardiovascular or neurological disorders, together with other medical and urological complications, may have an effect on survival outcomes, at baseline and during treatment from patients treated with androgen pathway inhibitors (API). Material and Methods: A retrospective study of a consecutive series of patients diagnosed with mCRPC between 2010 and 2018 treated with API in the first line setting in a single center. Results: Seventy-three patients met the inclusion criteria. Baseline prognostic factors associated with worse survival were diabetes mellitus (DM) with insulin needs compared to patients without DM [hazard ratio (HR) = 0.19, p = 0.025], hypertension (HTN) (HR = 0.46, p = 0.035), and a history of stroke (HR = 0.16, p < 0.001). However, previous history of hypercholesterolemia, arrythmias, and cognitive disorders did not result in a significant worsening on survival. During treatment, patients who developed de novo HTN had the best progression free survival (PFS) (HR = 0.38, p = 0.048) and overall survival (OS) (HR 0.08, p = 0.012) compared with patients with previous HTN. Other factors related to worse outcomes included the presence of heart failure (HR = 0.31, p = 0.001), the requirement for major opioids for pain relief (HR = 0.33, p = 0.023), and the presence of bilateral ureterohydronephrosis (HR = 0.12, p = 0.008). Conclusions: Some comorbidities may be strongly involved in patient outcomes when receiving API for mCRPC. In this sense, collaborative networking between specialists and caregivers treating prostate cancer (PC) patients should be recommended, focusing on MS features, cardiovascular and neurological disorders in order to anticipate medical and surgical complications.

الإتاحة: https://doi.org/10.1177/17562872211043341Test

المؤلفون: Serrano Domingo, Juan José, Alonso Gordoa, Teresa, Lorca Álvaro, Javier, Molina-Cerrillo, Javier, Barquín García, Arantzazu, Martínez Sáez, Olga, Burgos Revilla, Javier, Carrato, Alfredo, Álvarez Rodríguez, Sara

مصطلحات موضوعية: FOS: Clinical medicine, 111403 Paediatrics, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified

الوصف: Supplemental material, sj-docx-1-tau-10.1177_17562872211043341 for The effect of medical and urologic disorders on the survival of patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide by Juan José Serrano Domingo, Teresa Alonso Gordoa, Javier Lorca Álvaro, Javier Molina-Cerrillo, Arantzazu Barquín García, Olga Martínez Sáez, Javier Burgos Revilla, Alfredo Carrato and Sara Álvarez Rodríguez in Therapeutic Advances in Urology

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::db696f56b74257b7f1e8ca8419169d37Test

المؤلفون: Barquín-García, Arantzazu, Molina-Cerrillo, Javier, Garrido, Pilar, Garcia-Palos, Daniel, Carrato, Alfredo, Alonso-Gordoa, Teresa

المصدر: European Journal of Internal Medicine ; volume 66, page 1-8 ; ISSN 0953-6205

مصطلحات موضوعية: Internal Medicine

الإتاحة: https://doi.org/10.1016/j.ejim.2019.05.020Test
https://api.elsevier.com/content/article/PII:S0953620519301785?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0953620519301785?httpAccept=text/plainTest

المؤلفون: Molina-Cerrillo, Javier, Barquin-García, Arantzazu, Alonso-Gordoa, Teresa

المصدر: Medicina Clínica (English Edition) ; volume 152, issue 4, page e23 ; ISSN 2387-0206

الإتاحة: https://doi.org/10.1016/j.medcle.2018.04.010Test
https://api.elsevier.com/content/article/PII:S2387020619300026?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2387020619300026?httpAccept=text/plainTest